The combination of trastuzumab and pertuzumab has become a cornerstone of HER2-positive breast cancer treatment, as the dual inhibition of HER2 leads to a more comprehensive blockade of HER2 signalling pathways, boosting anti-tumour activity [10,11]. This evidence concerns the gene ERBB2 and neoplasm.